Abstract:Pretargeting with bivalent effectors capable of bridging antitumor antibodies (affinity enhancement pretargeting) has been reported to provide superior results by affinity enhancement. Phosphorodiamidate morpholinos (MORFs) and other DNA analogues used for pretargeting are ideally suited as bivalent effectors since they are easily synthesized and the distance between binding regions, a determinant of binding, may be adjusted simply by lengthening the chain. We have shown by surface plasmon resonance that bivalent MORFs will provide superior affinity enhancement provided that suitable spacing exists between the binding regions. The goals of this study were to synthesize a bivalent MORF with a MAG(3) group attached for technetium-99m (Tc-99m) radiolabeling, investigate whether the bivalent MORF showed improved cell accumulation in culture compared to its corresponding monovalent MORF and compare biodistributions in normal mice and in pretargeted tumored mice. An excess of an amine derivatized 18 mer MORF with 6 nonbinding bases for spacing was reacted with Fmoc-L-beta-homoglutamic acid to form duplexes via their carboxylate groups and, after deprotection, conjugated with NHS-MAG(3) to attach the chelator. The anti-CEA antibody MN14 was conjugated with a 12 mer complementary MORF (i.e., cMORF). The binding behavior between radiolabeled monovalent and bivalent MORFs was compared in LS174T tumor cells at 4 degrees C pretargeted with MN14 cMORF. Biodistributions of radiolabeled monovalent and bivalent MORFs at 3 h postadministration were measured in normal mice and in tumor mice pretargeted with MN14 cMORF. In the pretargeted cells in culture, the accumulation of the bivalent MORF was significantly higher than the monovalent MORF (p = 0.002), thus providing strong evidence for affinity enhancement. In normal mice, whole body clearance of the bivalent and monovalent MORFs was equally rapid. In tumored mice, tumor accumulation of the radiolabeled bivalent MORF was significantly higher than that of the monovalent MORF. In conclusion, a bivalent MAG3 MORF was successfully synthesized and radiolabeled with 99mTc. While a pharmacokinetic effect for the higher tumor accumulations in pretargeted mice of the radiolabeled bivalent MORF cannot be excluded, the results may be best explained by affinity enhancement. Thus two monovalent MORFs were covalently conjugated into a bivalent MORF effector to improve tumor targeting by both pharmacokinetics and affinity enhancement influences.

An Improved Synthesis of NHS-MAG3 for Conjugation and Radiolabeling of Biomolecules with 99mtc at Room Temperature

An Improved Synthesis Of Nhs-Mag3 For Conjugation And Radiolabeling Of Biomolecules With Tc-99m At Room Temperature

Methods for MAG3 Conjugation and 99mtc Radiolabeling of Biomolecules

Convenient Synthesis and Bioevaluation of New MAG3 Analogs for Rhenium-Labeling of Antibodies IgG

Radiolabeling of MAG3-morpholino Oligomers with 188re at High Labeling Efficiency and Specific Radioactivity for Tumor Pretargeting.

Application and Development of N-hydroxysuccinimidyl S-acetylmercap to Acetyltriglycline in Antisense Imaging

2-Mercaptoacetylglycylglycyl (MAG2) As a Bifunctional Chelator for 99Mtc-Labeling of Cyclic RGD Dimers: Effect of Technetium Chelate on Tumor Uptake and Pharmacokinetics

Preparation and Stability Evaluation of Small Interference RNA Radiolabeled with ~(99)Tc~m

Synthesis and Preliminary Biological Evaluation of a Technetium-99M Labeled Thymidine Analog

Synthesis, Radiolabeling and in Vivo Biological Evaluation of 99Mtc-Labeled MAG3-based Bisnitroimidazole Complexes As Tumor Hypoxia Markers

A Novel Tc-99m-labeled and MAG<sub>3</sub>-chelated Arginine-Arginine-Leucine containing Peptide for Tumor Imaging in Hepatoma Xenografts Model

Facile synthesis of bis(hydroxamamide)-based tetradentate ligands for 99mTc-radiopharmaceutical.

Synthesis and Biodistribution of 99Tcm-MAG2-Ade as A Tumor Imaging Agent

A NEW BIFUNCTIONAL CHELATING AGENT Α,ε-N,n'-bis(l-cysteinyl)-l-lysine FOR RADIOLABELLING OF MONOCLONAL ANTIBODIES WITH TECHNETIUM-99M

An Efficient Method for the Site-Specific 99m Tc Labeling of Nanobody

Affinity Enhancement Pretargeting: Synthesis and Testing of a 99Mtc-Labeled Bivalent MORF

Synthesis and Biodistribution of 99Mtc-Peptides Conjugated Adenine As Tumor Imaging Agents

Preparation and radiolabeling of human serum albumin (HSA)-coated magnetite nanoparticles for magnetically targeted therapy.

Glutaraldehyde mediated conjugation of amino-coated magnetic nanoparticles with albumin protein for nanothermotherapy.

Preparation of 188Re-Mag3 and in Vivo Evaluation in Mice

Facile synthesis of bis(hydroxamamide)-based tetradentate ligands for Tc-radiopharmaceutical